Letter: Lithium and M.R.I.H. in tardive dyskinesia.
D000284:Administration, Oral; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects; D002254:Carbonates / Q000008:administration & dosage / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D004316:Doxepin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000627:therapeutic use*; D009074:Melanocyte-Stimulating Hormones / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D010640:Phenothiazines; D010906:Pituitary Hormone-Releasing Hormones / Q000037:antagonists & inhibitors*; D051381:Rats; D012075:Remission, Spontaneous
D014150:Antipsychotic Agents; D002254:Carbonates; D009842:Oligopeptides; D010640:Phenothiazines; D010906:Pituitary Hormone-Releasing Hormones; D004316:Doxepin; D009074:Melanocyte-Stimulating Hormones; D008094:Lithium